| __timestamp | ACADIA Pharmaceuticals Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 7461000 |
| Thursday, January 1, 2015 | 90804000 | 13047000 |
| Friday, January 1, 2016 | 186456000 | 11253000 |
| Sunday, January 1, 2017 | 255062000 | 13933000 |
| Monday, January 1, 2018 | 265758000 | 29514000 |
| Tuesday, January 1, 2019 | 325638000 | 37121000 |
| Wednesday, January 1, 2020 | 388661000 | 67929000 |
| Friday, January 1, 2021 | 396028000 | 118818000 |
| Saturday, January 1, 2022 | 369090000 | 159371000 |
| Sunday, January 1, 2023 | 402466000 | 213894000 |
Unleashing insights
In the competitive world of biopharmaceuticals, operational efficiency is key. Over the past decade, ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, BioCryst's SG&A expenses grew by approximately 2,800% during the same period, indicating a strategic shift towards scaling operations. Notably, in 2023, BioCryst's expenses reached nearly 53% of ACADIA's, up from just 23% in 2014. This data highlights the dynamic strategies of these companies as they navigate the challenges of the pharmaceutical industry. Understanding these trends provides valuable insights into their operational priorities and market positioning.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared